Akebia Therapeutics Inc AKBA

US Biotechnology

$0.90 ▼ -2.48% ($-0.02)

⬇️ Below Yest. Low

Open $0.92

Prev Close $0.92

Day Range $0.89 – $0.93

52W Range $0.81 – $3.20

Market Cap $248.34M

Beta 0.21

EPS (TTM) $-0.11

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-03-20
Shares Out.	268,260,000
Website	akebia.com/ ↗
Phone	13026587581
Employees	194
Revenue	$49.1M
Gross Profit	$38.7M
Net Income	-$8.9M
Free Cash Flow	$40.3M
Total Assets	$349.7M
Total Liabilities	$324.6M
Equity	$25.0M

About Akebia Therapeutics Inc

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Inc is a publicly traded company under the ticker symbol AKBA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.